Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial

Bibliographic Details
Main Authors: Burtness, Barbara, Bourhis, Jean P, Vermorken, Jan B, Harrington, Kevin J, Cohen, Ezra EW
Format: Online
Language:English
Published: BioMed Central 2014
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4289298/

Similar Items